Search the GHTC website

Global health R&D delivers for Alabama

US government investment in global health R&D has delivered

$196.8 million
to Alabama research institutions
2,500+ new jobs
for Alabama
Alabama's top USG-funded global health R&D institutions

Alabama's top USG-funded global health R&D institutions

University of Alabama at Birmingham
$144 million
Southern Research Institute
$45.8 million
SunFire Biotechnologies LLC
$1.3 million
Auburn University
$1.2 million
GeneCapture Inc.
$1.2 million
University of South Alabama (Including College of Medicine)
$1.2 million
CFD Research Corporation
$701 thousand
Adjuvax LLC
$600 thousand
Cnine Biosolutions Inc.*
$415 thousand
FoodSource Lure Corporation
$257 thousand
SIO2 Medical Products Inc.
$173 thousand

Alabama's top areas of global health R&D by USG funding

Bacterial pneumonia & meningitis
Other coronaviruses (including MERS, SARS)
Hepatitis B
Neglected tropical diseases
Kinetoplastid diseases
Reproductive health
Bunyaviral diseases (including CCHF, RVF, SFTS)
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Hepatitis C
Multi-disease/health area R&D
Rheumatic fever
Global health R&D at work in Alabama

The University of Alabama at Birmingham Heersink School of Medicine operates the Antiviral Drug Discovery and Development Center (AD3C), funded by the US National Institutes of Health. AD3C focuses on developing drug therapies for diseases such as influenza, West Nile virus, chikungunya, dengue, and coronaviruses, including COVID-19. Researchers work to target and inhibit enzymes essential for viral replication. The viruses that AD3C targets are of high priority for the US government as the global burden of these diseases is enormous, and many also pose a risk to US citizens. Southern Research in Birmingham is supporting AD3C in screening potential compounds.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: NIAID